Production (Stage)
OS Therapies Incorporated
OSTX
$1.67
$0.042.45%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 574.51% | 254.13% | 23.96% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.93% | 56.91% | 1.59% | -- | -- |
| Operating Income | -184.93% | -56.91% | -1.59% | -- | -- |
| Income Before Tax | -52.64% | -14.00% | 17.15% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.64% | -14.00% | 17.15% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.64% | -14.00% | 17.15% | -- | -- |
| EBIT | -184.93% | -56.91% | -1.59% | -- | -- |
| EBITDA | -185.21% | -56.99% | -1.65% | -- | -- |
| EPS Basic | 31.31% | 21.88% | 35.86% | -- | -- |
| Normalized Basic EPS | 37.64% | 28.97% | 35.60% | -- | -- |
| EPS Diluted | 31.31% | 21.88% | 35.86% | -- | -- |
| Normalized Diluted EPS | 37.64% | 28.97% | 35.60% | -- | -- |
| Average Basic Shares Outstanding | 137.28% | 57.22% | 24.90% | -- | -- |
| Average Diluted Shares Outstanding | 137.28% | 57.22% | 24.90% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |